Recursion Pharmaceuticals (NASDAQ:RXRX) CEO Sells $94,798.30 in Stock

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) CEO Najat Khan sold 28,298 shares of the company’s stock in a transaction on Monday, March 9th. The stock was sold at an average price of $3.35, for a total transaction of $94,798.30. Following the completion of the transaction, the chief executive officer owned 2,262,085 shares of the company’s stock, valued at $7,577,984.75. This trade represents a 1.24% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Najat Khan also recently made the following trade(s):

• On Monday, December 22nd, Najat Khan sold 124,403 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $4.41, for a total value of $548,617.23.

Recursion Pharmaceuticals Price Performance

RXRX stock traded down $0.01 during mid-day trading on Wednesday, hitting $3.43. 14,332,931 shares of the stock were exchanged, compared to its average volume of 20,210,064. The business has a fifty day moving average price of $4.07 and a 200 day moving average price of $4.61. Recursion Pharmaceuticals, Inc. has a 12 month low of $2.98 and a 12 month high of $7.18. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.50 and a quick ratio of 5.50. The stock has a market capitalization of $1.81 billion, a price-to-earnings ratio of -2.32 and a beta of 0.97.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its quarterly earnings data on Wednesday, February 25th. The company reported ($0.21) EPS for the quarter, beating the consensus estimate of ($0.28) by $0.07. The firm had revenue of $35.54 million for the quarter, compared to analyst estimates of $24.56 million. Recursion Pharmaceuticals had a negative return on equity of 63.98% and a negative net margin of 863.37%.The company’s revenue was up 671.7% on a year-over-year basis. During the same period in the prior year, the company earned ($0.53) EPS. On average, sell-side analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current year.

Wall Street Analysts Forecast Growth

RXRX has been the topic of several research reports. JPMorgan Chase & Co. raised shares of Recursion Pharmaceuticals from a “neutral” rating to an “overweight” rating and lifted their price target for the stock from $10.00 to $11.00 in a research note on Wednesday, December 17th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research note on Thursday, January 22nd. Morgan Stanley set a $11.00 target price on shares of Recursion Pharmaceuticals in a report on Wednesday, December 17th. Wall Street Zen upgraded shares of Recursion Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Saturday, February 28th. Finally, UBS Group set a $11.00 price target on shares of Recursion Pharmaceuticals in a research report on Wednesday, December 17th. Two equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $9.40.

Institutional Trading of Recursion Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. grew its holdings in shares of Recursion Pharmaceuticals by 18.6% in the fourth quarter. Vanguard Group Inc. now owns 47,187,759 shares of the company’s stock worth $192,998,000 after purchasing an additional 7,407,606 shares during the last quarter. State Street Corp raised its holdings in Recursion Pharmaceuticals by 38.7% during the 4th quarter. State Street Corp now owns 25,333,888 shares of the company’s stock valued at $103,616,000 after buying an additional 7,064,963 shares during the last quarter. Norges Bank bought a new stake in Recursion Pharmaceuticals during the 4th quarter valued at $23,473,000. ARK Investment Management LLC boosted its position in Recursion Pharmaceuticals by 11.2% during the 4th quarter. ARK Investment Management LLC now owns 37,316,856 shares of the company’s stock valued at $152,626,000 after buying an additional 3,771,357 shares during the period. Finally, Bank Pictet & Cie Europe AG purchased a new stake in Recursion Pharmaceuticals during the 3rd quarter valued at $7,954,000. Institutional investors own 89.06% of the company’s stock.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.